This month public health officials in Ontario, Canada published a bombshell report summarizing the correlation between COVID-19 vaccination and heart damage.  The report, entitled Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval, sought to estimate rates of myocarditis and pericarditis following COVID-19 mRNA vaccine by product, age, sex, dose number and inter-dose interval.  It took into consideration all vaccination data within the Province of Ontario which has a population of 14.7 million.

According to the research,

There were 19,740,741 doses of mRNA vaccines administered and 297 reports of myocarditis/pericarditis meeting our inclusion criteria. Among these, 69.7% occurred following the second dose of COVID-19 mRNA vaccine and 76.8% occurred in males. The median age of individuals with a reported event was 24 years. The highest reporting rate of myocarditis/pericarditis was observed in males aged 18-24 years following [the Moderna vaccine] as the second dose; the rate in this age group was 5.1…times higher than the rate following [the Pfizer vaccine] as the second dose. Overall reporting rates were higher when the inter-dose interval was shorter (i.e., ≤30 days) for both vaccine products.

Graph from study. “mRNA-1273” is the Moderna and “BNT162b2” is Pfizer.

In the report’s conclusion, health officials state,

Our analyses suggest that modifications to mRNA COVID-19 vaccine programs relating to age-based product considerations and the use of longer inter-dose intervals may reduce the risk of [heart-related] events.